- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
8
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
8 companies
AbbVie
Market Cap: US$397.1b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$227.73
7D
0.2%
1Y
19.2%
Merck
Market Cap: US$298.3b
Operates as a healthcare company worldwide.
MRK
US$119.05
7D
-1.4%
1Y
45.7%
Travere Therapeutics
Market Cap: US$4.5b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$52.04
7D
13.6%
1Y
258.9%
Mesa Laboratories
Market Cap: US$593.1m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$105.48
7D
1.5%
1Y
8.6%
Waters
Market Cap: US$35.3b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$355.53
7D
-2.7%
1Y
3.9%
BioLife Solutions
Market Cap: US$1.3b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$26.10
7D
-2.1%
1Y
18.5%
Sotera Health
Market Cap: US$4.7b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$16.19
7D
3.6%
1Y
41.6%
Repligen
Market Cap: US$7.5b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$130.59
7D
6.8%
1Y
2.4%